Document Detail

Dehydroepiandrosterone inhibits CD40/CD40L expression on human umbilical vein endothelial cells induced by interferon gamma.
MedLine Citation:
PMID:  19015047     Owner:  NLM     Status:  MEDLINE    
Many studies indicated that the CD40/CD40 ligand (CD40L) pathway plays an important role in the pathogenesis of atherosclerosis. It has been demonstrated a protective role of dehydroepiandrosterone (DHEA) against atherosclerosis. The major purpose of our present work was to assess whether DHEA could decrease the expression of CD40 and CD40L on human umbilical vein endothelial cells (HUVECs) induced by interferon gamma (IFN-gamma). We found that DHEA inhibited IFN-gamma-induced expression of CD40 and CD40L in a dose-dependent manner. Moreover, DHEA inhibited IFN-gamma-induced activation of extracellular signal regulated kinase (ERK1/2). The important role of ERK1/2 in DHEA effect was further confirmed by using ERK1/2 inhibitor U0126. These findings suggest that DHEA can inhibit the expression of molecules involved in the inflammatory process in endothelial cells activated with IFN-gamma. Such antagonism is at least partially mediated through the modulation of ERK1/2 pathway. Therefore, DHEA may be considered as a potential preventive intervention for atherosclerosis.
Yan Li; Zunen Xia; Ming Wang
Related Documents :
22198947 - Intestinal epithelial cell-derived semaphorin 7a negatively regulates development of co...
3918107 - Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma.
6408177 - Induction of ia and h-2 antigens on a macrophage cell line by immune interferon.
16266317 - Ifn-gamma enhances bovine macrophage responsiveness to mycobacterium bovis: impact on b...
22984457 - Ablation of dihydroceramide desaturase confers resistance to etoposide-induced apoptosi...
17593667 - Harnessing nkt cells for therapeutic applications.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-11-17
Journal Detail:
Title:  International immunopharmacology     Volume:  9     ISSN:  1878-1705     ISO Abbreviation:  Int. Immunopharmacol.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-26     Completed Date:  2009-04-30     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  100965259     Medline TA:  Int Immunopharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  168-72     Citation Subset:  IM    
Department of Clinical Laboratory, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / pharmacology*
Antigens, CD40 / antagonists & inhibitors*,  biosynthesis
Atherosclerosis / immunology*,  prevention & control
Butadienes / pharmacology
CD40 Ligand / antagonists & inhibitors*,  biosynthesis
Cells, Cultured
Dehydroepiandrosterone / pharmacology*
Endothelium, Vascular / drug effects*,  immunology
Enzyme Inhibitors / pharmacology
Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors,  metabolism
Interferon-gamma / pharmacology
Nitriles / pharmacology
Signal Transduction
Umbilical Veins / cytology
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Antigens, CD40; 0/Butadienes; 0/Enzyme Inhibitors; 0/Nitriles; 0/U 0126; 147205-72-9/CD40 Ligand; 53-43-0/Dehydroepiandrosterone; 82115-62-6/Interferon-gamma; EC Signal-Regulated MAP Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pyruvate kinase type-II isozyme in Plasmodium falciparum localizes to the apicoplast.
Next Document:  Effects of Colostrinin on gene expression-transcriptomal network analysis.